Statin use among older Finns stratified according to cardiovascular risk
- 277 Downloads
Statin use has increased in older age groups, although there is little evidence for the benefits of statin therapy in the elderly, especially in low-risk persons. The aim of this paper is to describe recent trends in the prevalence and incidence of statin use among the Finnish older population, according to the person’s estimated cardiovascular (CV) event risk.
We conducted a register study covering the whole community-dwelling population of Finland, aged >70 years in 2000–2008 (N = 883,051). Data on reimbursed purchases of statins, antidiabetic and CV drugs, and pre-existing CV diseases were retrieved from comprehensive national registers. We stratified each person into low, moderate or high CV risk category, and according to age (70–74, 75–79, and >80 years) and sex.
Between 2000 and 2008, the age-sex-standardized prevalence of statin use tripled from 12.2 % to 38.7 % (rate ratio 3.0, 95 % CI 3.0–3.1), and the incidence almost doubled (from 3.7 % to 6.8 %; rate ratio 1.8, 95 % CI 1.8–1.9). The prevalence and incidence of statin use were consistently highest among high-risk persons. The greatest relative increases were observed in persons aged >80 years and in those at low risk; however, the proportion of statin users at low CV risk remained the same (∼7 % of all users).
Statin prescribing is shifting towards older age groups. A substantial increase in prevalence and incidence was seen across all risk categories, but the channeling of statin use towards high-risk persons remained unchanged.
KeywordsStatins Elderly Prevalence Incidence Cardiovascular risk
This study was financially supported by a research grant from the Social Insurance Institution of Finland (10/26/2007) and the Turku University Hospital Research Fund (EVO). Eveliina Upmeier was also supported by the research fund of Turku City Hospital (EVO).
Conflict of interest
The authors declare that they have no conflict of interest.
- 9.Taylor F, Ward K, Moore TH, et al (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD00481642Google Scholar
- 10.Miettinen TA, Pyörälä K, Olsson AG, for the Scandinavian Simvastatin Study Group et al (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Study (4S). Circulation 96:4211–4218PubMedCrossRefGoogle Scholar
- 15.Hunt D, Young P, Simes J, for the LIPID investigators et al (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 134:931–940PubMedGoogle Scholar
- 29.Kildemoes HW, Hendriksen C, Andersen M (2011) Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug. doi: 10.1002/pds.2039
- 31.Carey I, DeWilde S, Shah SM, Harris T, Whincup PH, Cook DG (2010) Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment? Nutr Metab Cardiovasc Dis. doi: 10.1016/j.numecd.2010.09.10
- 32.Glynn RJ, Koenig W, Nordestgaard BG, Shephard J, Ridker PM (2010) Rosuvastatin for primary prevention in older persons with elevated c-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 152:488–496PubMedGoogle Scholar
- 36.Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R (2011) Statiinien käyttö yleistyy myös vanhimmissa ikäluokissa. Suom Lääkäril 66:1930–1933 [in Finnish]Google Scholar